Scopulariopsis brevicaulis (S. brevicaulis) is a saprophytic fungus commonly found in soil, vegetables, air, and decaying organic waste (1). To date, there are eight species of Scopulariopsis that cause human infections. Of these, Scopulariopsis brevicaulis is non- dermatophyte filamentous fungus that rarely causes infections in humans (2, 3). However, recent studies reported an increase in the number of infections caused by this fungus (4). S. brevicaulis causes onychomycosis with an estimated rate of 3-10% (5). The most important clinical manifestation of onychomycosis is distal and lateral subungual onychomycosis (DLSO) (6, 7). S. brevicaulis infections can occur in the smooth skin and subcutaneous tissues. Disseminated S. brevicaulis infections like endocarditis, sinusitis, endophthalmitis, pneumonia, and brain abscess have also been reported (5, 8). These types of infections are difficult to treat and cause high fatality rate particularly in immunocompromised patients (5, 9). Several predisposing risk factors like familial dermatoses, trauma, diabetes mellitus, and peripheral circulatory insufficiency are commonly associated with S. brevicaulis infections (4).
Recent studies have also reported inefficiency of commonly used antifungal agents like amphotericin B (AMB) against S. brevicaulis, which represents a major concern (10). Molecular tools and genomic sequencing are commonly used for the identification of fungi. Recent studies have highlighted the genetic variability among S. brevicaulis isolates from different clinical sources, necessitating molecular approaches for the accurate identification and phylogenetic analysis (11).
Several genomic regions, including D1/D2, EF-1α, and ITS have been successfully utilized to differentiate the species among Scopulariopsis and related genera. Molecular techniques provide faster, more sensitive, and more accurate identification of dermatophytes compared to the culture methods (3). Traditional methods are time-consuming and occasionally produce unreliable results. Additionally, relatively late development of characteristic brown-powder configuration of S. brevicaulis colonies presents a further diagnostic challenge (12, 13).
Internal transcribed spacer regions (ITS1 and ITS2) can be used as molecular targets for the identification of intra-species variation in S. brevicaulis and for the phylogenetic analysis. This genetic region, situated between the small (18S) and large subunits (28S) of rRNA genes in the fungal genome, is known for its variability among different fungal strains and species. By comparing these sequences with reference databases such as GenBank, researchers can confirm the identity of S. brevicaulis isolated from the clinical or environmental samples (8).
A thorough taxonomic molecular study related to S. brevicaulis is still lacking in Kirkuk city, Iraq. In order to improve our understanding about diversity and genetic capabilities of this fungus we endeavoured to isolate S. brevicaulis from the skin lesions and identify to molecular level. This would assist in defining the species spectrum and relative frequencies of Scopulariopsis in clinical samples. Phylogenetic tree was then characterized based on the ITS sequence analysis. Finally, the in vitro antifungal sensitivity test was also determined using disc diffusion method.
Primer | Sequences 5’-3’ | Product size (bp) |
Forward | 5`-TCCGTAGGTGAACCTGCGG-3` | 550 |
Reverse | 5`-TCCTCCGCTTATTGATATGC-3` |
Clinical samples | |||||||
Fungal isolates (25) | Bacterial isolates (5) | ||||||
Mold | No. (%) | Yeast | No. (%) |
Gram negative | No. (%) |
Gram positive |
No. (%) |
Scopulariopsis brevicaulis | 1 (4%) |
Candida albicans | 7 (28%) |
Pseudomonas aeruginosa | 2 (40%) |
--- | --- |
Trichophyton mentagrophytes | 14 (56%) | Candida glabrata | 3 (12%) |
Klebsiella spp | 1 (20%) |
Staphylococcus aureus | 2 (40%) |
Accession number | Submission date | Similarity (%) | Query coverage (%) | Number of Nucleotide differences | Evolutionary distances | Country of submission |
KX923976.1 | 2017 | 98.96 | 98 | 6 | 0.006743741 | Netherlands |
OL589623.1 | 2022 | 98.98 | 99 | 6 | 0.01056835 | South Korea |
OP752128.1 | 2022 | 98.63 | 99 | 5 | 0.0042839377 | Turkey |
LC638842.1 | 2021 | 98.63 | 99 | 5 | 0.006508003 | Basrah Iraq |
OW982815.1 | 2022 | 99.14 | 99 | 4 | 0.0042428491 | Belgium |
KP641165.1 | 2015 | 99.13 | 98 | 3 | 0.004022939 | Iran |
EU821474.1 | 2015 | 99.48 | 98 | 3 | 0.0043055723 | Colombia |
MT576462.1 | 2020 | 99.48 | 98 | 3 | 0.0042817352 | China |
AY625065.1 | 2016 | 99.48 | 99 | 3 | 0.000547002 | USA |
KP132734.1 | 2015 | 99.49 | 99 | 3 | 0.012336815 | Australia |
MT316372.1 | 2020 | 99.49 | 99 | 3 | 0.0008799436 | Italy |
OR366529.1 | 2023 | 99.14 | 99 | 2 | 0.003763237 | India |
MF156019.1 | 2019 | 99.31 | 99 | 2 | 0.000723214 | Czech Republic |
AY773332.1 | 2004 | 99.65 | 98 | 2 | 0.002655759 | Australia |
Antifungal agents | Inhibition zone diameter (mm) |
Ketoconazole (KCA) | 15 mm |
Clotrimazole (CLO) | 0 |
Fluconazole (FLU) | 0 |
Amphotericin B (AMB) | 0 |
Nystatin (NY) | 0 |
Scopulariopsis brevicaulis is known to cause a variety of infections in humans, ranging from superficial skin infections to potentially life-threatening invasive mycoses (28). Despite its clinical significance, data on the prevalence of S. brevicaulis in skin infections in Kirkuk city, Iraq is limited. Thus, we attempted to isolate and identify S. brevicaulis from nail and skin infections. S. brevicaulis was recovered from 4% (n=1) of our fungal positive clinical samples. This lower prevalence rate of S. brevicaulis among fungal infections aligns with other literature data. A study done by Petanović et al (4) reported that only 2.2% of the fungal isolates was S. brevicaulis. In a study conducted by Azar et al (29), a lower prevalence rate of S. brevicaulis was observed with only 3.30% of diabetic patients being affected. Similarly, the prevalence of S. brevicaulis was also low in Korea with low reported rates (1.23% and 1.41%) (30). Furthermore, Turkish researchers demonstrated that only 3% of onychomycosis was caused by S. brevicaulis (20). Dhib et al. (31) also reported that only 0.3% of fungal positive nail cases were S. brevicaulis. Additionally, Bassiri-Jahromi and Khaksar demonstrated that S. brevicaulis is responsible for 2.1% of non-dermatophytic onychomycoses cases (32). Consistent with our results, Tosti et al. found S. brevicaulis in 3.9% of positive cases (33). Similarly, S. brevicaulis was identified in only 3.5% (28). On the other hand, some studies indicate higher prevalence rates of S. brevicaulis in onychomycoses, at 42.8% (34) and 43.5% (35). Variation of prevalence rate might be attributed to the geographic differences in mold distribution, variations in diagnostic criteria of onychomycosis, and the use of different culture methods (30). Other fungal isolates were also identified. Trichophyton spp. exhibited the highest prevalence rate (56%) followed by Candida spp. that accounted for 40%. These results agree with the findings of Mushıb et al (20) and Naik et al (36).
The ITS 1 region of our isolate was successfully amplified using PCR, similar to those reported in other researches (20). By sequencing the ITS region of S. brevicaulis, researchers can identify variations in the nucleotide sequences distinguishing different strains within the species (27). These variations provide insights into the genetic diversity, population structures, epidemiology, pathogenicity, and response to the antifungal treatments as well as evolutionary relationships among different isolates of S. brevicaulis.
To the best of our knowledge, this is the first study employing ITS based on phylogeny to determine the genetic variation in S. brevicaulis. Our phylogenetic tree revealed that the isolated fungus belongs to the same clade as those reported in the USA (accession number AY625065.1). However, it differs from the isolates found in the same country Iraq (Basrah), as well as in neighbouring countries like Iran and Turkey. This suggests that there are evolutionary distances between the isolates within the same region, which might contribute to the development of antifungal resistance.
Thus, focusing on intra-species variation of S. brevicaulis in a single country enables the researchers to identify distinct genetic variants or clades within S. brevicaulis populations across different regions or environments within the country. Furthermore, it assists in understanding which ITS variants are more prevalent in specific regions or environments within the country providing insights into the environmental factors affecting fungal distribution. Our findings agree with the previous data (37) showing the resistance of S. brevicaulis to the most antifungal agents particularly amphotericin B and fluconazole, except for ketoconazole, which displayed an inhibition zone of 13.4 mm. These drugs are the most important antifungals commonly used for the prophylaxis and treatment of mold infections. Numerous studies on in vitro antifungal activity and their combinations against clinical isolates of S. brevicaulis have confirmed it as a multi-drug resistant pathogen (38-40). Even with advancements in antifungal treatments, managing onychomycosis is still difficult, with over 25% of the patients showing incomplete or no response to treatment (30, 41, 42).
Multi-drug resistance pattern observed on the current and previous studies highlights the challenging in the treatment and management of infections caused by S. brevicaulis. More researches are required for understanding the resistance mechanisms, and exploring alternative treatment options to improve the patient outcomes and address the challenges posed by this pathogen.
Despite these findings, our study has some limitations. Firstly, it was based on a single isolate of S. brevicaulis which restricts the generalizability of our findings and highlights the need for more extensive sampling. Secondly, the study was confined to the isolates from Kirkuk city. Expanding the geographic scope would offer a more comprehensive understanding of the evolutionary relationships and distribution patterns of S. brevicaulis.
This study highlights the importance of S. brevicaulis identification in diabetic patients due to its multi-drug resistant property against antifungal drugs. Accurate identification of S. brevicaulis is vital for selecting the appropriate treatments to prevent severe mycoses. Furthermore, DNA sequencing and phylogenetic analysis showed genetic divergence from the strains reported in other countries and moderate evolutionary distance from those found in the same country (Basrah, Iraq). Thus, large-scale clinical trials using advanced molecular techniques are needed to monitor the evolutionary changes and resistance profiles of S. brevicaulis, guiding the development of effective treatments.
The authors express their gratitude to Department of Biology, College of Science, University of Kirkuk, for their assistance and support on this project.
Ethical Considerations
University of Kirkuk, Science College, Biology Department Ethics Committee approved the study under the code number ScB20.
Authors’ Contributions
All authors contributed equally to the preparation of this research article including, study concept and design, data collection, analysis and interpretation, and drafting and revision of the manuscript.
The author(s) received no financial support for the research or publication of this article.
Conflicts of Interest
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |